English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Nowadays anthracycline are frequently included in the adjuvant management of breast cancer. As a result, many of the patients who present with recurrent breast cancer have already received anthracyclines5. The palliative intent of systemic chemotherapy in MBC patients should be respected when choosing a strategy for its administration. In addition the decision to administer combination chemotherapy should be guided by the performance status of the patient as well as the need to control visceral metastases6.

research in oncology

Navelbine and Capecitabine (NavCap) versus NavCap Followed by Weekly Docetaxel as First-Line Treatment for Patients with HER-2 Negative Metastatic Breast Cancer